Cancer researchers led by Dr. Daniel De Carvalho (the principal investigator) at Princess Margaret Cancer Centre have merged epigenetic alterations, “liquid biopsy,” and ML to design a blood test to classify and detect cancer at its earliest phases.
The results, posted online this week in Nature, define not only a method to spot cancer, but hold commitment of being capable of finding it earlier when it is more effortlessly treated and long before signs ever appear, claims Dr. De Carvalho, who is Senior Scientist in University Health Network at the cancer center.
“We are very eager at this phase,” claims Dr. De Carvalho. “A major issue in cancer is how to spot it early. It has been a very difficult issue of how to find that cancer-specific 1-in-a-billion mutation in the blood, specifically at earlier phases, where the number of tumor DNAs in the blood are minimal.
Speaking of blood tests, diabetics might shortly be capable of passing on the conventional blood test having the need to prick the finger to calculate their levels of glucose. A group from the University of Bath has designed an adhesive non-invasive patch that draws out glucose from fluid among cells across hair follicles that are separately authorized via a series of miniature sensors employing a tiny electric current.
“A non-invasive (needle-less) way to calculate blood sugar has established to be a difficult objective to gain,” a professor from the Department of Pharmacy & Pharmacology, Richard Guy, claimed to the media in an interview. “The closest that has been attained has needed either the implantation of a pre-standardized sensor through an insertion of a single needle or at least a single-point standardization with a classic ‘finger-stick.’ The monitor designed at Bath pledges a truly standardization-free approach, a necessary contribution in the fight to battle the ever-rising worldwide occurrence of diabetes.”